Radio and PodcastRadio and PodcastLive Radio & Podcasts
Understanding BiTE Immunotherapy: How Bispecific T-Cell Engagers Target Cancer artwork
Health

Understanding BiTE Immunotherapy: How Bispecific T-Cell Engagers Target Cancer

CancerCast by Weill Cornell Medicine

Mar 20, 2026Health

Bispecific T-cell engager, or BiTE, therapy is an immunotherapy approach that helps the body’s own immune system target cancer cells by bringing immune cells and cancer cells together. In this episode of CancerCast, Dr....

About This Episode

Understanding BiTE Immunotherapy: How Bispecific T-Cell Engagers Target Cancer is an episode from CancerCast by Weill Cornell Medicine. Bispecific T-cell engager, or BiTE, therapy is an immunotherapy approach that helps the body’s own immun...

Podcast

This episode belongs to CancerCast.

Listen Online

Use the player on this page to stream the episode online.

Episode Details

Published Mar 20, 2026, audio available.

Questions About This Episode

What is Understanding BiTE Immunotherapy: How Bispecific T-Cell Engagers Target Cancer about?

Bispecific T-cell engager, or BiTE, therapy is an immunotherapy approach that helps the body’s own immune system target cancer cells by bringing immune cells and cancer cells together. In this episode of CancerCast, Dr. Manish Shah is joined by Dr. Mateo Mejia to explain how this form of antibody-based treatment works by directly connecting T cells and cancer cells. It is a new treatment in the arsenal of immunotherapy to treat cancer. They explore common side effects, as well as similarities and differences between BiTEs and other forms of immunotherapy. BiTE immunotherapy prevents cancer cells from being able to hide from the natural immune system, helping it to better recognize and attack the cancer. BiTEs are becoming an important treatment tool for several cancers, including multiple myeloma, lymphoma, lung cancer, and uveal melanoma. Drs. Shah and Mejia discuss the future direction and expansion of BiTE therapy, including ongoing research to bring these treatments to patients earlier in their cancer treatment journeys. Guest: Mateo Mejia Saldarriaga, MD, Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine and an Assistant Attending Physician at NewYork-Presbyterian Hospital. Host: Manish Shah, MD, Chief of Solid Tumor Service and Director of Gastrointestinal Oncology at Weill Cornell Medicine and NewYork-Presbyterian Hospital.

Where can I listen to Understanding BiTE Immunotherapy: How Bispecific T-Cell Engagers Target Cancer?

You can listen to Understanding BiTE Immunotherapy: How Bispecific T-Cell Engagers Target Cancer online on Radio and Podcast. Open the player on this page to stream the available audio.

Which podcast is Understanding BiTE Immunotherapy: How Bispecific T-Cell Engagers Target Cancer from?

Understanding BiTE Immunotherapy: How Bispecific T-Cell Engagers Target Cancer is an episode from CancerCast by Weill Cornell Medicine.

How long is this episode?

The episode duration depends on the source podcast feed and may not always be available.

When was this episode published?

This episode was published on Mar 20, 2026.

Can I save Understanding BiTE Immunotherapy: How Bispecific T-Cell Engagers Target Cancer for later?

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Are there related episodes from CancerCast?

Yes. This page shows related episodes from CancerCast when more episodes are available from the podcast feed.

Quick Answers About This Episode

Where can I listen to Understanding BiTE Immunotherapy: How Bispecific T-Cell Engagers Target Cancer?

You can listen to Understanding BiTE Immunotherapy: How Bispecific T-Cell Engagers Target Cancer on this page when the episode audio is available from the podcast feed.

Which podcast is this episode from?

Understanding BiTE Immunotherapy: How Bispecific T-Cell Engagers Target Cancer is from CancerCast by Weill Cornell Medicine.

What are the episode details?

Published Mar 20, 2026